These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21339995)

  • 1. Exploring the immunoproteome for ovarian cancer biomarker discovery.
    Martin K; Ricciardelli C; Hoffmann P; Oehler MK
    Int J Mol Sci; 2011 Jan; 12(1):410-28. PubMed ID: 21339995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
    Shi JX; Qin JJ; Ye H; Wang P; Wang KJ; Zhang JY
    Expert Rev Mol Diagn; 2015 Jun; 15(6):829-52. PubMed ID: 25959246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
    Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
    Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis.
    Zhu Q; Liu M; Dai L; Ying X; Ye H; Zhou Y; Han S; Zhang JY
    Autoimmun Rev; 2013 Oct; 12(12):1123-8. PubMed ID: 23806562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usage of cancer associated autoantibodies in the detection of disease.
    Dudas SP; Chatterjee M; Tainsky MA
    Cancer Biomark; 2010; 6(5-6):257-70. PubMed ID: 20938086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the humoral immune response to cancer.
    Murphy MA; O'Leary JJ; Cahill DJ
    J Proteomics; 2012 Aug; 75(15):4573-9. PubMed ID: 22300580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
    Cheng Y; Li Q; Sun G; Li T; Zou Y; Ye H; Wang K; Shi J; Wang P
    Sci Rep; 2024 Apr; 14(1):9757. PubMed ID: 38684875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies as biomarkers for ovarian cancer.
    Chatterjee M; Tainsky MA
    Cancer Biomark; 2010-2011; 8(4-5):187-201. PubMed ID: 22045353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies for cancer detection: still cause for excitement?
    Nolen BM; Lokshin AE
    Cancer Biomark; 2010; 6(5-6):229-45. PubMed ID: 20938084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies to tumor-associated antigens: reporters from the immune system.
    Tan EM; Zhang J
    Immunol Rev; 2008 Apr; 222():328-40. PubMed ID: 18364012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunomics using autoantibody signatures for biomarker discovery.
    Caron M; Choquet-Kastylevsky G; Joubert-Caron R
    Mol Cell Proteomics; 2007 Jul; 6(7):1115-22. PubMed ID: 17376768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer.
    Philip R; Murthy S; Krakover J; Sinnathamby G; Zerfass J; Keller L; Philip M
    J Proteome Res; 2007 Jul; 6(7):2509-17. PubMed ID: 17547437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibody biomarkers for the detection of serous ovarian cancer.
    Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
    Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
    Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
    Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Repertoires of Circulating Autoantibodies' Specificities as a Tool for Identification of the Tumor-Associated Antigens: Current Problems and Solutions.
    Belousov PV
    Biochemistry (Mosc); 2021 Oct; 86(10):1225-1242. PubMed ID: 34903148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma.
    Dai L; Ren P; Liu M; Imai H; Tan EM; Zhang JY
    Clin Immunol; 2014; 152(1-2):127-39. PubMed ID: 24667685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
    Fortner RT; Damms-Machado A; Kaaks R
    Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.
    Liu W; Peng B; Lu Y; Xu W; Qian W; Zhang JY
    Autoimmun Rev; 2011 Apr; 10(6):331-5. PubMed ID: 21167321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.